Taletrectinib
Brand names: Ibtrozi · Active ingredient: Taletrectinib Adipate
In short: IBTROZI® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) .
What is Taletrectinib used for?
IBTROZI® (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) .
Taletrectinib dosage
Select patients for the treatment of locally advanced or metastatic NSCLC with IBTROZI based on the presence of ROS1 rearrangement(s) in tumor specimens .
An FDA-approved test to detect ROS1 rearrangement(s) for selecting patients for treatment with IBTROZI is not currently available.
Before initiating IBTROZI, evaluate liver function tests (including ALT, AST, and bilirubin), electrolytes, ECG, and uric acid .
The recommended dosage of IBTROZI is 600 mg orally once daily on an empty stomach (no food intake at least 2 hours before and 2 hours after taking IBTROZI) until disease progression or unacceptable toxicity.
Take IBTROZI at approximately the same time each day. Swallow IBTROZI capsules whole. Do not open, chew, crush, or dissolve the capsule prior to swallowing.
Avoid food or drink containing grapefruit during treatment with IBTROZI.
Minimize sun exposure and use sun protection, including broad-spectrum sunscreen, during treatment with IBTROZI and for at least 5 days after discontinuation .
Missed Dose
If a dose is missed, take the next dose at its scheduled time on the following day.
Vomiting
If vomiting occurs at any time after taking a dose, take the next dose at its scheduled time on the following day.
The recommended dosage reductions for the management of adverse reactions are provided in Table 1.
Dosage Reduction | Recommended Dosage
First Dose Reduction | 400 mg once daily
Second Dose Reduction | 200 mg once daily
Permanently discontinue IBTROZI capsules in patients unable to tolerate 200 mg once daily.
The recommended dosage modifications of IBTROZI for the management of adverse reactions are provided in Table 2.
Adverse Reaction | Severity* | Dosage Modification
Hepatotoxicity (Elevation of ALT or AST) | Grade 3 (>5 - 20 × ULN) | Withhold IBTROZI until recovery to Grade ≤1 or baseline.
If resolved within 6 weeks, resume IBTROZI at a reduced dose level.
If unresolved after 6 weeks, permanently discontinue IBTROZI.
Recurrence:
If resolved within 6 weeks, resume IBTROZI at a reduced dose level.
If unresolved after 6 weeks, permanently discontinue IBTROZI.
Grade 4 (>20 × ULN) | Withhold IBTROZI until recovery to Grade ≤1 or baseline.
If resolved within 6 weeks, resume IBTROZI at a reduced dose level.
If unresolved after 6 weeks, permanently discontinue IBTROZI.
Recurrence:
Permanently discontinue IBTROZI.
ALT or AST ≥3 × ULN with concurrent total bilirubin ≥2 × ULN (in the absence of cholestasis or hemolysis) | Permanently discontinue IBTROZI.
ILD/pneumonitis
| Grade 1 | Withhold IBTROZI if ILD/pneumonitis occurs or is suspected until recovery to Grade 0 or baseline.
If resolved within 6 weeks, resume IBTROZI at the same dose level.
If unresolved after 6 weeks, permanently discontinue IBTROZI. …
How to take Taletrectinib — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Hepatotoxicity
Advise patients of the risk of hepatotoxicity and of the need for laboratory tests to monitor liver function during treatment with IBTROZI and to immediately contact their healthcare providers if they experience symptoms of hepatotoxicity .
Interstitial Lung Disease (ILD)/Pneumonitis
Inform patients of the risk of ILD/pneumonitis during treatment with IBTROZI and to contact their healthcare provider immediately if they experience new or worsening pulmonary symptoms indicative of ILD/pneumonitis .
QTc Interval Prolongation
Inform patients of the risk of QT interval prolongation during treatment with IBTROZI and advise patients to contact their healthcare provider immediately for any symptoms of QT interval prolongation .
Hyperuricemia
Advise patients of the risk of hyperuricemia during treatment with IBTROZI and to contact their healthcare provider if they experience signs or symptoms associated with hyperuricemia . …
Warnings & precautions
Do not take this medicine if: None.
IBTROZI can cause hepatotoxicity, including drug-induced liver injury and fatal adverse reactions.
In the pooled safety population , based on laboratory values, 88% of patients treated with IBTROZI experienced increased aspartate aminotransferase (AST), including 10% Grade 3 or 4. Increased alanine aminotransferase (ALT) occurred in 85% of patients treated with IBTROZI, including 13% Grade 3 or 4. The median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).
Increased AST or ALT each led to dose interruption in 7% of patients. Increased AST and ALT leading to dose reduction occurred in 5% and 9% of patients, respectively. Increased AST and ALT each led to permanent discontinuation of IBTROZI in 0.3% of patients. Other liver-related adverse reactions leading to permanent discontinuation of IBTROZI were hepatotoxicity (0.6% of patients) and increased bilirubin (0.3% of patients).
Concurrent elevations in AST or ALT ≥3 times the upper limit of normal (ULN) and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 2 (0.6%) patients treated with IBTROZI. Fatal liver events occurred in 2 (0.6%) patients.
Monitor liver function tests (AST, ALT, and bilirubin) prior to administration of IBTROZI, every 2 weeks during the first 2 months of treatment, and then monthly thereafter as clinically indicated with more frequent testing in patients who develop transaminase elevations. Withhold, then resume at reduced dose upon improvement, or permanently discontinue IBTROZI based on severity .
IBTROZI can cause severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis.
In the pooled safety population , interstitial lung disease (ILD)/pneumonitis occurred in 2.3% of patients treated with IBTROZI, including Grade 3 or 4 in 1.1% of patients. …
Taletrectinib side effects
The following adverse reactions are discussed in greater detail in the WARNINGS AND PRECAUTIONS section:
Hepatotoxicity
Interstitial Lung Disease/Pneumonitis
QTc Interval Prolongation
Hyperuricemia
Myalgia with Creatine Phosphokinase Elevation
Skeletal fractures
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS section and below reflects exposure to IBTROZI as a single agent at 600 mg orally once daily until disease progression or unacceptable toxicity in 352 patients with ROS1-positive NSCLC (N=337) and other solid tumors (N=15). Among the 352 patients who received IBTROZI, 68% were exposed for at least 6 months, and 47% were exposed for greater than 1 year. In this pooled safety population, the most common (≥20%) adverse reactions were diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue. The most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT, increased AST, decreased neutrophils, increased creatine phosphokinase, decreased lymphocytes, increased magnesium, decreased hemoglobin, and increased triglycerides.
Locally Advanced or Metastatic ROS1-Positive NSCLC
The safety of IBTROZI was evaluated in the TRUST-I and TRUST-II studies . …
Drug interactions
Strong and Moderate CYP3A Inhibitors
Avoid concomitant use with strong or moderate CYP3A inhibitors.
Taletrectinib is a CYP3A substrate. Concomitant use of IBTROZI with a strong or moderate CYP3A inhibitor increases taletrectinib exposure , which may increase the risk of IBTROZI adverse reactions.
Strong and Moderate CYP3A Inducers
Avoid concomitant use with strong or moderate CYP3A inducers.
Concomitant use of IBTROZI with a strong or moderate CYP3A inducer decreases taletrectinib exposure , which may reduce the effectiveness of IBTROZI.
Gastric Acid Reducing Agents
Avoid concomitant use with proton pump inhibitors (PPI) and H2 receptor antagonists. Administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI .
Concomitant use of a proton pump inhibitor decreases taletrectinib exposure , which may reduce the effectiveness of IBTROZI.
Avoid concomitant use of IBTROZI with other drug(s) with a known potential to prolong the QTc interval, such as antiarrhythmic drugs. If concomitant use cannot be avoided, adjust the frequency of monitoring as recommended . Withhold IBTROZI if the QTc interval is >500 msec or the change from baseline is >60 msec .
IBTROZI causes QTc interval prolongation . …
About this medicine
IBTROZI (taletrectinib) capsules contain taletrectinib adipate, a kinase inhibitor for oral use. The molecular formula for taletrectinib adipate is C23H24FN5O•C6H10O4 and the molecular weight is 551.61 g/mol. The chemical name is 3-{4-[(2R)-2-aminopropoxy]phenyl}-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo [1,2b]pyridazin-6-amine monoadipate. The chemical structure of taletrectinib adipate is as follows:
Figure 1: Structure of Taletrectinib Adipate
(R) Indicates chiral center
Taletrectinib adipate is a white to yellowish powder and is practically insoluble or insoluble in water, anhydrous ethanol, isopropanol, acetonitrile, and n-hexane, sparingly soluble in methanol, and slightly soluble in N-methyl pyrrolidone. The aqueous solubility is pH dependent and decreases with increasing pH. The pKa1 is 5.39 and pKa2 is 8.65.
IBTROZI (taletrectinib) capsules for oral use are supplied as immediate-release hard capsules containing 272 mg of taletrectinib adipate (equivalent to 200 mg of taletrectinib free base). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 51ac8e52-3269-4102-8dc8-dba22d82128c. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate